Prazosin

ATC Code C02CA01

Prazosin

Definition

A synthetic piperazine derivative and an alpha-1 adrenergic receptor inhibitor used primarily as an anti-hypertensive. Prazosin's effects are most pronounced in the large resistance vessels (i.e. arterioles) and result in a decrease in total systemic vascular resistance (SVR) without a rebound or reflex tachycardia. To a lesser extent, this agent also decreases the tone of the bladder sphincter, thereby allowing the opening of the bladder into the urethra and thus relieving the urinary conditions associated with benign prostatic hypertrophy.

Also known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine, 2-[4-(2-furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline, Furazosin, PRAZOSIN — per NCIT

Also identified as

Indications

Disease Relation Source
Benign prostatic hyperplasia may treat MEDRT · Public domain (U.S. Government work)
Hypertensive disorder may treat MEDRT · Public domain (U.S. Government work)
Raynaud disease may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Cardiovascular system may treat a disease of this organ DERIVED · CC BY 4.0
Genitourinary system may treat a disease of this organ DERIVED · CC BY 4.0
Male reproductive system may treat a disease of this organ DERIVED · CC BY 4.0
Prostate may treat a disease of this organ DERIVED · CC BY 4.0
Reproductive system may treat a disease of this organ DERIVED · CC BY 4.0

5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.